Gainers

• Kodiak Sciences (NASDAQ:KOD) stock rose 49.0% to $33.91 during Thursday's pre-market session. The market value of their outstanding shares is at $1.3 billion.
• Firefly Neuroscience (NASDAQ:AIFF) stock increased by 26.78% to $2.13. The company's market cap stands at $26.3 million.
• Precigen (NASDAQ:PGEN) stock increased by 19.03% to $3.69. The company's market cap stands at $1.0 billion. The company's, Q4 earnings came out yesterday.
• Rani Therapeutics Hldgs (NASDAQ:RANI) shares increased by 14.81% to $1.31. The company's market cap stands at $111.1 million. As per the press release, Q4 earnings came out today.
• Enanta Pharma (NASDAQ:ENTA) shares rose 13.31% to $13.79. The company's market cap stands at $353.1 million.
• Advanced Biomed (NASDAQ:ADVB) stock increased by 13.08% to $4.84. The company's market cap stands at $5.8 million.

Losers

• WAVE Life Sciences (NASDAQ:WVE) stock fell 57.7% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $2.2 billion.
• Artelo Biosciences (NASDAQ:ARTL) shares declined by 34.02% to $3.2. The market value of their outstanding shares is at $3.5 million.
• Icecure Medical (NASDAQ:ICCM) stock fell 21.57% to $0.46. The market value of their outstanding shares is at $43.0 million.
• EUDA Health Holdings (NASDAQ:EUDA) stock fell 20.49% to $9.12. The company's market cap stands at $28.8 million.
• Cibus (NASDAQ:CBUS) shares fell 19.87% to $2.3. The market value of their outstanding shares is at $198.5 million.
• Rockwell Medical (NASDAQ:RMTI) shares decreased by 18.95% to $0.84. The market value of their outstanding shares is at $40.9 million. As per the news, the Q4 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.